Use of aripiprazole for psychosis and agitation in dementia

International Psychogeriatrics

Volumn 18, Issue 2, 2006, Pages 335-340

  Laks, Jerson ^a,c   Miotto, Roberto ^b   Marinho, Valeska ^a   Engelhardt, Eliasz ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Integrated Unit of Mental Health   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOXAZOLAM; LORAZEPAM; PIRIBEDIL; SEDATIVE AGENT; THYROID HORMONE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CEREBROVASCULAR DISEASE; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; FEMALE; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; TREATMENT OUTCOME; URINE RETENTION;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; QUINOLONES; TREATMENT OUTCOME;

EID: 33744798470     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610205002541     Document Type: Article

References (16)

1. Abou-Gharbia, N. et al. (2004). Comparative study of the long-term effects of aripiprazole and olanzapine treatment on body weight. Poster presentation. World Psychiatric Association International Congress, Florence, Italy.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed.) Washington, D.C.: American Psychiatric Association.
3. Brodaty, H. et al. (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134-143.
4. De Deyn, P. P. et al. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946-955.
5. De Deyn, P. P. et al. (2003). Aripiprazole treatment for psychosis in patients with Alzheimer's disease. Poster presentation, ECNP, Prague.
6. DeLeon, A., Patel, N. C. and Crismon, M. L. (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics, 26, 649-666.
7. Engelhardt, E., Laks, J., Cavalcanti, J. L. S., Moreira, D. M., Brandão, L. and Rozenthal, M. (2003). Alzheimer's disease, limbic 1H-MRS and CDR stages. Journal of the Neurological Sciences, 214, 63.
8. Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T. and Altar, C. A. (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Europen Journal of Pharmacology, 441, 137-140.
9. Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J. and Brecher, M. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry, 60, 107-115.
10. Madhusoodanan, S., Brenner, R., Gupta, S., Reddy, H. and Bogunovic, O. (2004). Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectroscopy, 9, 862-867.
11. McQuade, R. D., Burris, K. D., Jordan, S., Tottori, K., Kurahashi, N. and Kikuchi, T. (2002). Aripiprazole: a dopamine-serotonin system stabilizer. International Journal of Neuropsychopharmacology, 5 (Suppl. 1), S176.
12. McQuade, R. D. et al. (2004). A comparison of weight gain during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Journal of Clinical Psychiatry, 65 (Suppl. 18), 47-56.
13. Street, J. S. et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry, 57, 968-976.
14. Streim, J. E., Brender, C. and Swanink, R. (2004). Flexible dose aripiprazole in psychosis of Alzheimer's dementia (AD). Poster presented at the Annual Meeting of the American Psychiatry Association (APA).
15. Tariot, P. N., Profenno, L. A. and Ismail, M. S. (2004). Efficacy of atypical antipsychotics in elderly patients with dementia. Journal of Clinical Psychiatry, 65 (Suppl. 11), 11-15.
16. Yokoi, F. et al. (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology, 27, 248-259.